News

Hyperglycemia, or high concentrations of sugar in the blood, can be brought to normal levels, or considerably reduced, in almost 70% of people with both Cushing’s syndrome and hyperglycemia following curative surgery or radiation therapy, a study has found. The report highlighted the need for close monitoring and adjusting medications…

Xeris Biopharma’s newly approved therapy Recorlev (levoketoconazole) is now available to patients in the U.S. through the specialty pharmacy PANTHERx Rare, the company announced in a press release. The therapy is prescribed for adults with endogenous Cushing’s syndrome for whom surgery is not possible or not effective. “The commercial…

The use of large amounts of corticosteroids over a prolonged period of time — as a topical treatment for a 4-year-old girl who had previously undergone a large skin graft — triggered Cushing’s syndrome in the child, according to a recent case report. The girl was examined by clinicians after…

A combination of medications that inhibit steroidogenesis — the process by which the body produces steroid hormones, like cortisol, from cholesterol — can be used to treat people with Cushing’s syndrome, allowing for adequate control of their cortisol levels until surgery, a case report highlighted. Such combinations may be especially…

A mediastinal paraganglioma, an extremely rare tumor located between the lungs, was found to be the cause of Cushing’s syndrome in a 40-year-old Chinese policeman, according to a recent case report. Doctors were particularly challenged by this case because the patient also had a pituitary tumor, which could have been…

In pregnant women, changes in DNA methylation — a chemical modification used to tone down gene expression or activity — may worsen Cushing’s syndrome caused by adrenal tumors, a study reported. Findings indicate these chemical changes cause tumors to grow faster and become larger in pregnant patients compared with patients…

Xeris Pharmaceuticals has selected the specialty pharmacy PANTHERx Rare to distribute Recorlev (levoketoconazole), the company’s therapy that was recently approved to treat adults with endogenous Cushing’s syndrome in whom surgery is not possible or not effective. “PANTHERx is proud to partner with Xeris to address the needs of adults…

Due to its effects on heart tissue, high levels of cortisol, like those seen in Cushing’s syndrome, may play a role in the development of cardiomyopathies — diseases of the heart muscle that make it harder for the heart to pump blood to the rest of the body —…

A team of researchers in China have identified, for the first time, a tumor cell that produces both adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH) — two hormones that promote excess cortisol levels and the development of Cushing’s syndrome. Specifically, this unique cell type was found in a rare…

The U.S. Food and Drug Administration (FDA) has approved Recorlev (levoketoconazole) to treat adults with endogenous Cushing’s syndrome for whom surgery is not an option or has not been effective. The therapy is expected to be available in the U.S. in the coming months. To ensure access to Recorlev,…